Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Generian logo — Thinking big about small molecule therapeutics.

Generian

Thinking big about small molecule therapeutics.

Founded 2019 United States Pittsburgh, United States 6 employees Venture round Health Care, Pharmaceutical

General Information

Company Name Generian
Founded Year 2019
Location United States Pittsburgh, United States
Employees 6
Industries Health Care, Pharmaceutical
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with Generian. To contact Generian, visit generian.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Generian compare?

A PDF of Generian and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Generian soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Generian

Generian is a healthcare and pharmaceutical startup based in the United States founded in 2019. The company focuses on revolutionizing small molecule therapeutics with the aim of addressing the limitations of biologics and improving the patient experience. Generian's unique drug discovery approach allows it to screen proteins of interest in their native cellular environment, enabling the discovery of small molecules against previously challenging drug protein targets.

Generian has internal programs for clinically validated targets, including FcRn and IL-4r alpha. In addition, the company has established research collaborations, such as the one with Astellas, to focus on novel targets. This diversified pipeline positions Generian as a potential game-changer in the pharmaceutical industry, with the ability to efficiently progress candidates through highly translational phenotypic screening.

Currently, there is no publicly disclosed information regarding Generian's last investment or the involved investors. For those interested in discovering more about Generian and its innovative approach to small molecule therapeutics, the company suggests reaching out to their team at [email protected].

No funding data available for Generian yet.

Generian Alternatives & Competitors

Generian vs
Advenchen Laboratories, LLC
Advenchen Laboratories, LLC

Pioneering novel therapies with promising small molecule kinase inhibitors for a brighter future in...

Venture round
6 employees
Biotechnology, Health Care
Generian vs
Sibylla Biotech
Sibylla Biotech Italy

Fold the future

Series A
41 employees
Biotechnology, Health Care

FAQ About Generian

Thinking big about small molecule therapeutics.
Generian was founded in 2019.
Generian is headquartered in Pittsburgh, United States.
Generian operates in Health Care and Pharmaceutical.
Generian has approximately 6 employees.
Top alternatives and competitors to Generian include Advenchen Laboratories, LLC, Sibylla Biotech. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Generian and Advenchen Laboratories, LLC are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Generian, https://bouncewatch.com/company/generian, updated 7 January 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout